Integrin Subunit Detection for Venous Thromboembolism Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing venous thromboembolism (VTE) face challenges due to high morbidity, misdiagnosis, and mortality rates, with traditional views on thrombus proteins being inadequate for accurate diagnosis and treatment.
Innovation Solution
A novel method involving the detection of integrin β1, β2, and β3 subunits in blood samples using substances that specifically bind to these subunits, such as antibodies or ligands, to diagnose VTE, including acute pulmonary embolism, chronic thromboembolic pulmonary hypertension, and deep venous thrombosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional phlebothrombosis theory-based diagnostic methods are used, then the diagnostic process is simple, but the diagnostic accuracy is low leading to high misdiagnosis rates
Solution Approach 1:
The patent changes the diagnostic parameter from traditional fibrin-only detection to detection of multiple proteins including fibrin, fibrinogen, and integrin subunits (β1, β2, β3). This parameter expansion enables more accurate differentiation between VTE and other conditions, directly resolving the contradiction by improving diagnostic accuracy through enhanced biochemical parameter measurement.
Solution Approach 2:
The diagnostic method employs a composite protein profile approach, analyzing multiple protein components simultaneously rather than relying on a single marker. This composite analysis of fibrin, fibrinogen, and integrin subunits creates a more robust diagnostic signature that improves accuracy while maintaining clinical feasibility.
2Loss of information
If traditional fibrin-based thrombus composition view is used, then the understanding of thrombus formation is simple, but the diagnostic capability is insufficient
Solution Approach 1:
The patent segments the thrombus composition analysis into distinct protein components: fibrin, fibrinogen, and integrin subunits (β1, β2, β3). This segmentation allows for targeted detection of each component's contribution to thrombus formation, recovering lost information about thrombus heterogeneity while using established immunological detection methods for each segment.
Solution Approach 2:
The patent uses integrin subunits as intermediary markers that bridge the gap between traditional fibrin detection and comprehensive thrombus characterization. These integrin proteins serve as mediators that provide additional information about platelet involvement and thrombus formation mechanisms without requiring direct observation of complex thrombus structure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a more accurate diagnostic tool by identifying increased levels of integrin subunits, indicating VTE, thereby improving diagnostic accuracy and potentially reducing misdiagnosis and mortality rates.
Implementation Method 1
a substance capable of specifically binding to the integrin β1 subunit, the integrin β2 subunit, and/or the integrin β3 subunit
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides a method for diagnosing venous thromboembolism (VTE), comprising: detecting the level of an integrin β1 subunit, an integrin β2 subunit, and/or an integrin β3 subunit in a blood sample. Also provided is a reagent kit for diagnosing VTE, comprising a substance capable of specifically binding to the integrin β1 subunit, the integrin β2 subunit, and/or the integrin β3 subunit.